Press Releases

 Apr 25, 2023, 07:30 ET  –  Poster presented at ARVO demonstrates PL9588 reduces intraocular pressure –  Data provides further support for topical administration of melanocortins for ocular inflammation CRANBURY, N.J., April 25, 2023 /PRNewswire/ — Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system, today announced […]

 Apr 19, 2023, 07:30 ET  $3.4 million in Gross Product Revenue 31% growth over 2Q23; 165% growth over 3Q22 $1.2 million in Net Product Revenue 22% growth over 2Q23; 469% growth over 3Q22 27% growth in prescriptions dispensed over 2Q23; 147% growth over 3Q22 5 consecutive quarters of double-digit growth CRANBURY, N.J., April 19, 2023

 Apr 18, 2023, 07:30 ET  –  International Journal of Molecular Sciences manuscript demonstrates robust pre-clinical data in two retinal disease models –  Studies further demonstrate broad utility of melanocortin agonists in treating inflammatory conditions, especially in the eye CRANBURY, N.J., April 18, 2023 /PRNewswire/ — Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that

 Mar 02, 2023, 07:30 ET  Oral PL8177 is gut restricted in rats, dogs and humans Bioinformatics data shows positive effects on enterocytes and infiltrating immune cells CRANBURY, N.J., March 2, 2023 /PRNewswire/ — Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system, today announced Frontiers in

 Feb 28, 2023, 07:30 ET  CRANBURY, N.J., Feb. 28, 2023 /PRNewswire/ — Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system, announced that the United States Patent and Trademark Office issued U.S. Patent No. 11,590,209, titled “Use of Bremelanotide in

 Feb 15, 2023, 07:30 ET  Phase 3 Pivotal Study of PL9643 in Patients with Dry Eye Disease Ongoing Patient Enrollment on Track Topline Results Currently Expected Mid-Calendar Year 2023 Phase 2 Clinical Study of Oral PL8177 in Patients with Ulcerative Colitis Commenced First Patient Dosed Planned Interim Analysis Targeted for First Half Calendar Year 2023 Topline Results Currently Expected

 Feb 10, 2023, 07:30 ET  CRANBURY, N.J., Feb. 10, 2023 /PRNewswire/ — Palatin Technologies, Inc. (NYSE American: PTN) will announce its second quarter fiscal year 2023 operating results on Wednesday, February 15, 2023, before the open of the U.S. financial markets. Palatin will also conduct a conference call and live audio webcast hosted by its

 Jan 19, 2023, 07:30 ET  –  BREAKOUT Study is Palatin’s third clinical program for the potential treatment of inflammatory diseases with melanocortin agonists –  Primary endpoint of the BREAKOUT Study is a 50% reduction in urine protein/creatinine (UP/Cr) ratio after six months of combined therapy (RAAS inhibition therapy plus bremelanotide) CRANBURY, N.J., Jan. 19, 2023

 Jan 18, 2023, 07:30 ET  Sells Net Operating Loss Tax Benefits Through New Jersey Economic Development Program CRANBURY, N.J., Jan. 18, 2023 /PRNewswire/ — Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system, today announced it has received approximately $4.7

 Jan 10, 2023, 07:30 ET  –  Collaboration with The William Harvey Research Institute and Queen Mary University of London –  PL-8177 displayed pro-resolving and anti-arthritic effects in rodents CRANBURY, N.J., Jan. 10, 2023 /PRNewswire/ — Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system, today announced Frontiers